Grants & Awards

 

To date, the company has raised over $7.5 million in private investments and an equivalent amount through numerous government and private grants. These grants provide an ongoing source of funding and do not have a dilutive effect on shareholder investments.

20/20 was one of only 56 companies nationwide selected to receive a 2007 award for innovative industrial research and development projects from the Advanced Technology Program (ATP), a program of the National Institute of Standards and Technology (NIST).

Technologies selected for ATP funding undergo an extensive, highly competitive, peer-reviewed process that evaluates the scientific and technical merit of each proposal, commercial potential and the potential for broad-based benefits to the nation if the technology were successfully developed.

In 2007, 20/20 GeneSystems was awarded an Israel-U.S. Binational Industrial Research and Development Foundation Grant (BIRD).  The aim of this joint development project was to develop and bring to market the first accurate blood test for the early detection of lung cancer, the leading cancer killer in much of the world.

In July of 2008, 20/20 was awarded a $650,000 Phase II SBIR award from the NIH to utilize the L-IHC technology with biomarkers associated with the response of breast tumors to targeted therapies. (This award will be the basis of our 2010 Bridge Award application.)

In 2010, 20/20 GeneSystems was awarded $3 million from National Cancer Institute to further develop personalized medicine tests utilizing our L-IHC technology.

In 2013, 20/20 GeneSystems was awarded a $1.2 million contract from the National Cancer Institute NCI (Contract #N44C031014-51) to develop a Companion Diagnostic for Prediction of Response to Targeted Therapies in Kidney Cancer. The objective is to validate a companion diagnostic to predict response to anti-angiogenic therapy (i.e. VEGFR inhibitors in patients with late stage kidney cancer, advanced clear cell renal cell carcinoma (ccRCC).

In 2015, 20/20 GeneSystems was awarded a $25,000 Life Sciences Impact grant.  The Life Sciences Impact grant was created to provide assistance to life science employers  and stimulate the growth of life sciences in Montgomery County, Maryland.  The goal of this research was to determine if 20/20 could introduce additional marker(s), either individually or as part of our early lung cancer detection test, that would provide insight into stage of Chronic Obstructive Pulmonary Disease (COPD) and assist in establishing the risk of that patient with COPD to develop lung cancer.